CLINICAL OUTCOMES OF AXITINIB VERSUS SUNITINIB AS A FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN JAPANESE PATIENTS

被引：0
|
作者：
Kiso, Yusuke
Inoue, Takamitsu
Nara, Taketoshi
Kanda, Sohei
Numakura, Kazuyuki
Tsuruta, Hiroshi
Saito, Mitsuru
Narita, Shintaro
Satoh, Shigeru
Habuchi, Tomonori
机构：
来源：
JOURNAL OF UROLOGY | 2018年 / 199卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP66-16
引用
收藏
页码：E874 / E874
页数：1
相关论文
共 50 条
  • [21] First-line therapy for metastatic renal cell carcinoma
    Sawhney, Paramvir
    Suyanto, Suyanto
    Michael, Agnieszka
    Pandha, Hardev
    JOURNAL OF CLINICAL UROLOGY, 2024, 17 (02) : 190 - 200
  • [22] Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] COST EFFECTIVENESS OF SUNITINIB AS FIRST-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN CHINA
    Shi, Q.
    Yin, H.
    Xuan, J.
    Wu, Y.
    Cheng, G.
    VALUE IN HEALTH, 2014, 17 (07) : A638 - A638
  • [24] Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
    Badran, Ahmed
    Elshenawy, Mahmoud A.
    Shahin, Amgad
    Aljubran, Ali
    Alzahrani, Ahmed
    Eldali, Abdelmoneim
    Bazarbashi, Shouki
    JCO GLOBAL ONCOLOGY, 2020, 6 : 19 - 26
  • [25] Risk of treatment failure after first-line sunitinib therapy in patients with metastatic renal cell carcinoma.
    Chen, Chi-Chang
    Hess, Gregory P.
    Liu, Zhimei
    Gesme, Dean H.
    Agarwala, Sanjiv S.
    Hill, Jerrold W.
    Guo, Min Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [26] Dosing schedules and outcomes in patients with first-line sunitinib for advanced renal cell carcinoma
    Kitamura, Hiroshi
    Inoue, Ryuta
    Shindo, Tetsuya
    Nishiyama, Naotaka
    Masumori, Naoya
    ANNALS OF ONCOLOGY, 2015, 26 : 102 - 102
  • [27] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Ruiz-Morales, Jose Manuel
    Swierkowski, Marcin
    Wells, J. Connor
    Fraccon, Anna Paola
    Pasini, Felice
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Sliwczynsk, Andrzej
    Ptak-Chmielewska, Aneta
    Teter, Zbigniew
    Beuselinck, Benoit
    Wood, Lori A.
    Yuasa, Takeshi
    Pezaro, Carmel
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 102 - 108
  • [28] Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
    Zhou, Ai-Ping
    Bai, Yuxian
    Song, Yan
    Luo, Hong
    Ren, Xiu-Bao
    Wang, Xiuwen
    Shi, Benkang
    Fu, Cheng
    Cheng, Ying
    Liu, Jiyan
    Qin, Shukui
    Li, Jun
    Li, Hanzhong
    Bai, Xianzhong
    Ye, Dingwei
    Wang, Jinwan
    Ma, Jianhui
    ONCOLOGIST, 2019, 24 (08): : E702 - E708
  • [29] Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Choueiri, T.
    Larkin, J.
    Albiges, L.
    Haanen, J. B.
    Schmidinger, M.
    Atkins, M. B.
    Mariani, M.
    Shnaidman, M.
    Di Pietro, A.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
    Vuorinen, Riikka-Liisa
    Paunu, Niina
    Turpeenniemi-Hujanen, Taina
    Reunamo, Taina
    Jekunen, Antti
    Kataja, Vesa
    Sintonen, Harri
    Purmonen, Timo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2019, 39 (10) : 5559 - 5564
12345